Preventing and Treating Missing Data in Longitudinal Clinical Trials : A Practical Guide
โ Scribed by Craig H. Mallinckrodt
- Publisher
- Cambridge University Press
- Year
- 2013
- Tongue
- English
- Leaves
- 186
- Series
- Practical Guides to Biostatistics and Epidemiology Ser.
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
Recent decades have brought advances in statistical theory for missing data, which, combined with advances in computing ability, have allowed implementation of a wide array of analyses. In fact, so many methods are available that it can be difficult to ascertain when to use which method. This book focuses on the prevention and treatment of missing data in longitudinal clinical trials. Based on his extensive experience with missing data, the author offers advice on choosing analysis methods and on ways to prevent missing data through appropriate trial design and conduct. He offers a practical guide to key principles and explains analytic methods for the non-statistician using limited statistical notation and jargon. The book's goal is to present a comprehensive strategy for preventing and treating missing data, and to make available the programs used to conduct the analyses of the example dataset.
โฆ Subjects
Clinical trials -- Longitudinal studies. ; Medical sciences -- Statistical methods. ; Regression analysis -- Data processing.
๐ SIMILAR VOLUMES
<P>Analyzing Longitudinal Clinical Trial Data: A Practical Guide provide practical and easy to implement approaches for bringing the latest theory on analysis of longitudinal clinical trial data into routine practice. This book, with its example-oriented approach that includes numerous SAS and R cod
<P>Analyzing Longitudinal Clinical Trial Data: A Practical Guide provide practical and easy to implement approaches for bringing the latest theory on analysis of longitudinal clinical trial data into routine practice. This book, with its example-oriented approach that includes numerous SAS and R cod
Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies ofte